Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IBRXNASDAQ:IMVTNASDAQ:MLTXNASDAQ:TRVI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIBRXImmunityBio$2.53-5.6%$2.63$1.83▼$7.63$2.23B0.335.57 million shs6.25 million shsIMVTImmunovant$14.46-0.7%$15.46$12.72▼$34.47$2.46B0.751.22 million shs754,314 shsMLTXMoonLake Immunotherapeutics$38.93+1.1%$38.43$31.42▼$58.26$2.49B1.31353,569 shs133,169 shsTRVITrevi Therapeutics$6.29+4.3%$6.27$2.30▼$7.39$628.33M0.621.20 million shs1.23 million shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIBRXImmunityBio-5.60%-10.92%-5.95%-26.02%-63.54%IMVTImmunovant-0.69%0.00%+0.07%-31.98%-51.08%MLTXMoonLake Immunotherapeutics+1.09%+3.48%-1.47%-7.92%-2.46%TRVITrevi Therapeutics+4.31%-3.23%+0.32%+36.74%+137.36%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationIBRXImmunityBio1.8395 of 5 stars3.61.00.00.01.91.70.6IMVTImmunovant2.6837 of 5 stars4.51.00.00.03.61.70.0MLTXMoonLake Immunotherapeutics3.1478 of 5 stars4.52.00.00.03.42.50.0TRVITrevi Therapeutics3.4715 of 5 stars4.72.00.00.03.53.30.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIBRXImmunityBio 3.20Buy$12.25384.19% UpsideIMVTImmunovant 2.90Moderate Buy$38.33165.10% UpsideMLTXMoonLake Immunotherapeutics 3.00Buy$78.71102.19% UpsideTRVITrevi Therapeutics 3.30Buy$17.56179.21% UpsideCurrent Analyst Ratings BreakdownLatest TRVI, MLTX, IMVT, and IBRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/20/2025IBRXImmunityBioPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Overweight$4.25 ➝ $5.005/20/2025TRVITrevi TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$24.00 ➝ $24.005/19/2025MLTXMoonLake ImmunotherapeuticsWolfe ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradePeer Perform ➝ Outperform$61.005/13/2025MLTXMoonLake ImmunotherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$78.00 ➝ $80.005/13/2025MLTXMoonLake ImmunotherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$66.00 ➝ $66.005/12/2025IBRXImmunityBioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.005/12/2025IBRXImmunityBioD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.005/5/2025IBRXImmunityBioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy4/30/2025MLTXMoonLake ImmunotherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$66.00 ➝ $66.004/28/2025IBRXImmunityBioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.004/23/2025IBRXImmunityBioD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.00(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIBRXImmunityBio$31.22M71.52N/AN/A($0.88) per share-2.88IMVTImmunovantN/AN/AN/AN/A$2.08 per shareN/AMLTXMoonLake ImmunotherapeuticsN/AN/AN/AN/A$8.15 per shareN/ATRVITrevi TherapeuticsN/AN/AN/AN/A$1.29 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIBRXImmunityBio-$583.20M-$0.58N/AN/AN/A-8,016.83%N/A-110.02%8/11/2025 (Estimated)IMVTImmunovant-$259.34M-$2.62N/AN/AN/AN/A-77.94%-69.82%6/4/2025 (Estimated)MLTXMoonLake Immunotherapeutics-$36.01M-$2.30N/AN/AN/AN/A-15.54%-15.09%8/6/2025 (Estimated)TRVITrevi Therapeutics-$29.07M-$0.45N/AN/AN/AN/A-63.31%-57.06%N/ALatest TRVI, MLTX, IMVT, and IBRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/4/2025Q4 2025IMVTImmunovant-$0.72N/AN/AN/AN/AN/A5/12/2025Q1 2025IBRXImmunityBio-$0.12-$0.15-$0.03-$0.15$17.50 million$16.52 million5/12/2025Q1 2025MLTXMoonLake Immunotherapeutics-$0.76-$0.63+$0.13-$0.63N/AN/A5/6/2025Q1 2025TRVITrevi Therapeutics-$0.13-$0.09+$0.04-$0.09N/AN/A3/18/2025Q4 2024TRVITrevi Therapeutics-$0.12-$0.11+$0.01-$0.11N/AN/A3/3/2025Q4 2024IBRXImmunityBio-$0.26-$0.15+$0.11-$0.09$8.74 million$7.55 million2/26/2025Q4 2024MLTXMoonLake Immunotherapeutics-$0.63-$0.72-$0.09-$0.72N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIBRXImmunityBioN/AN/AN/AN/AN/AIMVTImmunovantN/AN/AN/AN/AN/AMLTXMoonLake ImmunotherapeuticsN/AN/AN/AN/AN/ATRVITrevi TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIBRXImmunityBioN/A2.682.64IMVTImmunovantN/A6.046.04MLTXMoonLake ImmunotherapeuticsN/A25.5125.51TRVITrevi TherapeuticsN/A7.387.38Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIBRXImmunityBio8.58%IMVTImmunovant47.08%MLTXMoonLake Immunotherapeutics93.85%TRVITrevi Therapeutics95.76%Insider OwnershipCompanyInsider OwnershipIBRXImmunityBio76.79%IMVTImmunovant5.90%MLTXMoonLake Immunotherapeutics12.02%TRVITrevi Therapeutics18.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIBRXImmunityBio590882.62 million115.67 millionOptionableIMVTImmunovant120169.86 million159.84 millionOptionableMLTXMoonLake Immunotherapeutics264.01 million56.22 millionOptionableTRVITrevi Therapeutics2099.89 million58.13 millionOptionableTRVI, MLTX, IMVT, and IBRX HeadlinesRecent News About These CompaniesWoodline Partners LP Buys 2,606,370 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI)May 24 at 5:02 AM | marketbeat.comFrazier Life Sciences Management L.P. Boosts Stake in Trevi Therapeutics, Inc. (NASDAQ:TRVI)May 23 at 7:51 AM | marketbeat.comTrevi Therapeutics' (TRVI) Buy Rating Reiterated at Needham & Company LLCMay 23 at 1:27 AM | americanbankingnews.comNeedham & Company LLC Reaffirms "Buy" Rating for Trevi Therapeutics (NASDAQ:TRVI)May 22 at 8:12 AM | marketbeat.comVR Adviser LLC Reduces Stock Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI)May 22 at 6:53 AM | marketbeat.comTrevi Therapeutics Announces Additional Analyses from Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic CoughMay 20, 2025 | prnewswire.comPoint72 Asset Management L.P. Takes Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI)May 20, 2025 | marketbeat.comCubist Systematic Strategies LLC Invests $368,000 in Trevi Therapeutics, Inc. (NASDAQ:TRVI)May 19, 2025 | marketbeat.comDimensional Fund Advisors LP Grows Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI)May 19, 2025 | marketbeat.comTrevi Therapeutics, Inc. (NASDAQ:TRVI) Stock Holdings Increased by MPM Bioimpact LLCMay 16, 2025 | marketbeat.comWall Street Analysts See a 195.05% Upside in Trevi Therapeutics (TRVI): Can the Stock Really Move This High?May 14, 2025 | zacks.comTrevi Therapeutics, Inc. (TRVI) Q1 2025 Earnings Call TranscriptMay 11, 2025 | seekingalpha.comBarclays PLC Boosts Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI)May 10, 2025 | marketbeat.comTrevi Therapeutics, Inc.: Trevi Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdatesMay 9, 2025 | finanznachrichten.deTrevi Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdatesMay 9, 2025 | finance.yahoo.comTrevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Consensus Rating of "Buy" from AnalystsMay 9, 2025 | marketbeat.comMarshall Wace LLP Sells 38,203 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI)May 8, 2025 | marketbeat.comAlly Bridge Group NY LLC Lowers Stock Holdings in Trevi Therapeutics, Inc. (NASDAQ:TRVI)May 4, 2025 | marketbeat.comAcuta Capital Partners LLC Has $3.18 Million Stock Holdings in Trevi Therapeutics, Inc. (NASDAQ:TRVI)May 4, 2025 | marketbeat.comAcorn Capital Advisors LLC Invests $8.24 Million in Trevi Therapeutics, Inc. (NASDAQ:TRVI)May 4, 2025 | marketbeat.comBoothbay Fund Management LLC Takes $387,000 Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI)May 4, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTRVI, MLTX, IMVT, and IBRX Company DescriptionsImmunityBio NASDAQ:IBRX$2.53 -0.15 (-5.60%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$2.54 +0.01 (+0.40%) As of 05/23/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.Immunovant NASDAQ:IMVT$14.46 -0.10 (-0.69%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$14.47 +0.01 (+0.07%) As of 05/23/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.MoonLake Immunotherapeutics NASDAQ:MLTX$38.93 +0.42 (+1.09%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$38.98 +0.05 (+0.14%) As of 05/23/2025 04:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.Trevi Therapeutics NASDAQ:TRVI$6.29 +0.26 (+4.31%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$6.30 +0.00 (+0.08%) As of 05/23/2025 05:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain Advance Auto Parts Jumps on Surprise Earnings Beat Costco Stock at $1K: Dominance or Danger Zone? Williams-Sonoma: A Fundamentally Good Buy On Sale Now Snowflake Breaks Out! Can It Drift Higher in 2025 and Beyond? Alphabet Gets JPMorgan’s Vote of Confidence After Google I/O Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
